Skip to the policy article

Policy reading room

October 2026 peptide compounding: a draft policy and Peptides+ preview

HHS describes draft 503A enforcement discretion; Hims & Hers previews a future service. Neither establishes FDA product approval or current dispensing.

Draft status on October 29

At our October 29, 2026 check in US/Eastern time, Federal Register document 2026-22192 remained a public-inspection notice scheduled for October 30. It describes a draft, nonbinding HHS enforcement-discretion policy on 503A compounding while rulemaking continues. That record does not establish completed publication, an effective date or permanent listing. It addresses state-licensed pharmacies, federal facilities and licensed physicians, without announcing a 503B authorization. HHS says safety or quality concerns could prompt reconsideration.

FDA approval and manufacturing standards

FDA explains that compounded drugs are not FDA-approved: their safety, effectiveness and quality are not verified by the agency before marketing. It advises using them only when an approved drug cannot meet a patient’s medical needs. A compounding policy therefore answers a different question from a product approval.

For finished drugs, FDA distinguishes qualifying compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C) from 503B outsourcing facilities. The former is exempt from current good manufacturing practice (CGMP) requirements; the latter’s drugs are not. Read that distinction alongside the separate original-manufacturer condition below.

Exact preparations

Exact preparations

Match Appendix B’s identity and route.

On a narrow screen, scroll the table sideways to read both columns.

PreparationRoute
BPC-157 acetateFor BPC-157 acetate, subcutaneous, intramuscular, oral and topical use is listed; intravenous is excluded.
TB-500 acetate (fragment, not full-length thymosin beta-4)Subcutaneous or intramuscular.
Epitalon acetateSubcutaneous or intramuscular; intermittent courses.
Semax free baseIntranasal.
KPV acetateOral or topical.
MOTS-c acetateSubcutaneous or intramuscular.

Conditions

  1. Use an Appendix A substance.
  2. Match Appendix B’s identity and route.
  3. Use bulk from a section 510-registered facility, with valid certificates of analysis documenting Appendix B test results.
  4. Registered original manufacturers need CGMP and FD&C compliance, with physical locations on certificates. Registered intermediaries must document manufacturer and certificate validation.
  5. Report products, serious adverse events and quality issues to FDA and compounding and destination states. Use MedWatch for events and quality issues, regardless of causality. Labels need patient reporting instructions; product reports identify ingredient, unit strength, original manufacturer, facility identifier, form and route.
  6. Label it: “This is a compounded drug product. Not for resale.”
  7. Only one active ingredient, from Appendix A.
  8. Document adequate human oral bioavailability for the supplied oral formulation.
  9. Only FDA 510(k)-cleared syringes may serve as co-packaged or drug-containing delivery devices; noninjectable application remains unresolved.
  10. Meet other FD&C requirements, including sanitary conditions and patient-specific prescriptions.

The Peptides+ preview

Hims & Hers’ October 29 announcement previews Peptides+ and invites readers to a launch list. Planned offerings are sermorelin, glutathione, B12, NAD+ and L-carnitine, with BPC-157 and TB-500 later if allowable. The menu includes therapies beyond peptides. Its proposed model uses independent providers and licensed pharmacies. The announcement does not verify a current prescription, shipment, price or state eligibility.

The company’s forward-looking cautions cover launch timing, available treatments, regulatory changes and limited clinical data. We read this as a plan with stated uncertainties, not an established clinical result.

Reader questions

Which pharmacy would prepare the product?

FDA notes that online purchasers may not know the compounder’s identity or whether it is appropriately licensed and regulated. Ask the service to identify the pharmacy and provide a way to check it. Keep that response tied to the offer you are discussing.

Our assessment

Our provider ratings and historical clinical entries have not been revised by this policy update.

Scope and disclosure

This is a document-reading guide, not individual medical or legal advice. We have not audited a pharmacy, tested a formulation, verified current dispensing, pricing or state eligibility, or established clinical benefit. No clinician review is claimed.

Source documents

  1. Policy

    HHS

    Checked

  2. Notice 2026-22192

    Federal Register

    Checked

  3. Peptides+ announcement

    Hims & Hers

    Checked

  4. Compounding Q&A

    FDA

    Checked